BUY Dixon Technologies

PN3 approvals start trickling in; re-rating candidate

Electronic Manufacturing Services | Company Update | **March 10, 2026** | **CMP (Rs): 10,908 | TP (Rs): 15,200**

Per media articles (refer to link) , the Union Cabinet has approved changes to the Press Note 3 framework for FDI (we await official confirmation by the GoI). Press reports indicate that certain sectors, including EMS, could be moved to a simpler and faster track for FDI approvals with introduction of 'de minimis' thresholds. Dixon has received approval for its HKC JV, to manufacture display modules (offer double-digit EBITDAM); this raises level of backward integration in smartphones by 10-12% from 16-17% now. We believe such events improve the odds for PN3 approval coming through for the Vivo JV. As argued in our earlier report (Jan-26; De-rated on cyclical fears; structural upside intact), the street has been baking in a bear case due to a couple of near-term concerns (including pending PN3 approval for HKC and Vivo JV), while undervaluing the structural growth avenues, including possibility of i) TLA with HKC and ii) organic business win in Vivo in the absence of a JV. The two concerns are likely to be addressed, offering visibility to our base case (factors in organic volume ramp-up with Vivo), where we build in 48% FY25-28E EPS CAGR with industry leading return ratios of >30%. We reiterate BUY on Dixon with TP of Rs15,200.

Revision in PN3 a major positive; increases likelihood of approval for Vivo JV

Media articles reported that the Union Cabinet has approved changes to the PN3 framework for easing and simplifying the FDI approval process. The PN3 framework introduced in 2020 during Covid had effectively directed all FDI from China to take the government route rather than the much faster and simpler automatic route. While there is no government press release yet, media reports have indicated that the revised PN3 framework will allow FDI in certain non-crucial sectors (including EMS) to go through a faster/streamlined approval process rather than an exhaustive case-by-case scrutiny. There are also reports that 'de minimis' thresholds are being considered for allowing smaller FDI to move through the automatic approval route. These developments signal a shift in policy balance toward attracting more Chinese investment in manufacturing as opposed to blocking investments for national security which, in our view, is a structural positive. The precise categories/thresholds are expected to attain clarity once the formal notification is issued. We believe this relaxation increases the likelihood of PN3 approval for Dixon's JV with Vivo, which has been one of the key concerns over the past 8-10M.

HKC JV for display modules deepens Dixon's presence in component ecosystem

Dixon has received Press Note (PN) 3 approval from MEITY for its JV with China-based HKC, for display module manufacturing. This foray into display modules deepens Dixon's presence in the component ecosystem, with the level of backward integration in smartphones expected to rise by ~10-12% from 16-17% now. Per the Q3FY26 earnings call, mass production of display modules is set to commence from Q2FY27 (trials in Q1FY26). Given near-term pressure from PLI expiry in Mar-26, display module ramp-up (double-digit EBITDAM) will aid margin expansion. Dixon has already received approval for its JV with Q-tech for camera modules (BOM: 8-9%). Dixon targets achieving 40-45% backward integration via display modules, camera modules, enclosures (BOM: 8-9%).

Target Price – 12M	Dec-26
Change in TP (%)	**-**
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	39.3

Stock Data	**DIXON IN**
52-week High (Rs)	18,472
52-week Low (Rs)	9,620
Shares outstanding (mn)	60.8
Market-cap (Rs bn)	663
Market-cap (USD mn)	7,224
Net-debt, FY26E (Rs mn)	(5,685.7)
ADTV-3M (mn shares)	0.5
ADTV-3M (Rs mn)	8,982.1
ADTV-3M (USD mn)	97.8
Free float (%)	67.6
Nifty-50	24,261.6
INR/USD	91.8

Shareholding, Dec-25	
Promoters (%)	28.8
FPIs/MFs (%)	18.7/29.1

Price Performance

(%)	**1M**	**3M**	**12M**
Absolute	(6.0)	(11.7)	(16.9)
Rel. to Nifty	0.4	(6.2)	(23.1)

1-Year share price trend (Rs)



Dixon Technologies: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	**FY24**	**FY25**	**FY26E**	**FY27E**	**FY28E**
Revenue	176,909	388,601	493,104	699,820	887,815
EBITDA	6,976	15,076	18,835	26,539	40,049
Adj. PAT	3,677	6,356	8,530	13,808	21,661
Adj. EPS (Rs)	61.5	105.5	141.6	229.2	359.5
EBITDA margin (%)	3.9	3.9	3.8	3.8	4.5
EBITDA growth (%)	36.1	116.1	24.9	40.9	50.9
Adj. EPS growth (%)	43.2	71.5	34.2	61.9	56.9
RoE (%)	24.7	27.0	23.1	27.5	32.4
RoIC (%)	25.0	32.7	30.2	37.9	44.2
P/E (x)	177.4	60.0	77.0	47.6	30.3
EV/EBITDA (x)	93.9	43.5	34.8	24.7	16.4
P/B (x)	38.5	21.8	15.1	11.6	8.5
FCFF yield (%)	-	0.4	0.8	0.6	2.1

Source: Company, Emkay Research

Chirag Jain
chirag.jain@emkayglobal.com
+91-22-66242428

Mayank Pandey
mayank.pandey@emkayglobal.com
+91 22 66121340

Nandan Pradhan
nandan.pradhan@emkayglobal.com
+91-22-66121238

Marazbaan Dastur
marazbaan.dastur@emkayglobal.com
+91-22-66121281

Exhibit 1: We maintain our volume estimates for FY26-28

Client-wise smartphone volume	Earlier estimates			Base-case (Vivo JV not built in)			Comments
(mn units)	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**	
Domestic	***38.5***	***45.6***	***53.9***	***38.5***	***45.6***	***53.9***	
Oppo	4.3	4.3	5.2	4.3	4.3	5.2	Another big client for Dixon, with expanding relations; Dixon contributes to 25% of Oppo's domestic volumes
Vivo	-	6.9	11.4	-	6.9	11.4	We have now built in lower volumes from Vivo, assuming organic scale up in volumes for Dixon
One Plus	-	-	-	-	-	-	Not yet a client
Realme	4.1	4.1	4.5	4.1	4.1	4.5	For Realme, Dixon had called out 0.45mn/mth volumes; Realme is the more affordable brand of the BBK Group (models priced below Xiaomi)
Iqoo	-	-	-	-	-	-	Not yet a client
Nokia	0.6	0.4	0.4	0.6	0.4	0.4	Dixon is the sole supplier for Nokia; volumes for Nokia remain limited
Transsion (Itel, Tecno, Infinix)	8.5	6.8	8.1	8.5	6.8	8.1	Most of the models are in the sub-Rs20k range for Infinix and Techno, and sub-Rs15k for Itel, where volume erosion is likely owing to the higher DRAM prices
Motorola	9.5	9.4	9.4	9.5	9.4	9.4	Here, Dixon has lost market share to a peer; 85% of volumes being supplied by Dixon now vs 100% earlier; though absolute volumes to increase for Motorola
Xiaomi	6.2	6.1	7.0	6.2	6.1	7.0	Xiaomi has seen market share loss, curtailed volumes for FY26E-28E to factor this in; Dixon expects 45% market share eventually
Compal/Google	0.1	0.1	0.1	0.1	0.1	0.1	Google Pixel has relatively smaller volumes with higher ASPs
Samsung	5.2	4.5	4.7	5.2	4.5	4.7	Dixon has a sub-contracting arrangement with Samsung; we assume some decline here as well; ASPs for this are nearly 1/4th of the normal ASPs, hence revenue to see limited impact
New ODM	-	3.1	3.2	-	3.1	3.2	Dixon has highlighted new ODM from Q1FY27, with 0.5mn/mth unit potential; we factor in ~0.25mn/mth units
	-	-	-				
Exports	*4.3*	*8.2*	*10.3*	*4.3*	*8.2*	*10.3*	Exports to see growth going ahead, largely driven by Motorola
	-	-	-				
Total domestic, including Samsung	**38.5**	**45.6**	**53.9**	**38.5**	**45.6**	**53.9**	
Total domestic, excluding Samsung	**33.3**	**41.1**	**49.2**	**33.3**	**41.1**	**49.2**	
Exports	4.3	8.2	10.3	4.3	8.2	10.3	We consider an improvement in exports, largely driven by Motorola
	0	**0**	**0**				
Grand total, including Samsung	**42.8**	**53.8**	**64.2**	**42.8**	**53.8**	**64.2**	
Grand total, excluding Samsung	**37.6**	**49.3**	**59.5**	**37.6**	**49.3**	**59.5**	

Source: Company, Emkay Research

Exhibit 2: We build in ~33-35% volume contribution from Motorola (including exports) during FY26E-28E

Domestic smartphone volumes for key clients, per the base case (mn units)	FY26E	FY27E	FY28E	Commentary
Motorola (including exports)	**13.5**	**17.4**	**19.4**	**Dixon has 85% volume share in Motorola (vs 100% earlier) and is seeing strong growth in the business with Motorola via exports**
Oppo	4.3	4.3	5.2	Dixon manufactures 25% of Oppo's domestic volume, via growing relationships
Realme	4.1	4.1	4.5	Dixon manufactures for Realme via its partnership with ODM Longcheer
Xiaomi	6.2	6.1	7.0	Dixon targets 45% market share with Xiaomi vs 25% currently
Vivo		6.9	11.4	We build in organic scale-up in Vivo without the JV in our base case
Dixon's total smartphone volumes (ex-Samsung, mn units)	**37.5**	**49.3**	**59.5**	We build in 26% volume CAGR over FY26E-28E, driven by organic scale-up in Vivo, aided by strong growth in Motorola
Share of key clients in Dixon's total volumes (ex-Samsung, %)	**FY26E**	**FY27E**	**FY28E**	
Motorola (including exports)	**36.0**	**35.2**	**32.5**	
Oppo	11.5	8.8	8.8	
Realme	10.8	8.2	7.5	
Xiaomi	16.6	12.4	11.8	
Vivo	0.0	14.0	19.1	

Source: Company, Emkay Research

Exhibit 3: We had earlier highlighted that even with 2% Royalty, the TLA route for Dixon would be largely EPS-neutral

PNL under the JV route with HKC	FY27E	FY28E	FY29E	FY30E	Commentary
Display Modules Manufacturing	**10.9**	**13.0**	**24.1**	**36.9**	Displays for internal consumption (mobiles and IT hardware) and external consumption
ASP (Rs/unit) - 12% of the BOM cost	1,118	1,261	1,307	1,352	ASP at 12% of Mobile ASP, as display modules are ~12% of BOM
JV revenues (Rs mn)	12,203	16,445	31,437	49,851	
EBITDA margin (%)	**12.0%**	**12.0%**	**12.0%**	**12.0%**	Per the management, display modules offer healthy double-digit margins; assumed 12%
JV EBITDA (Rs mn)	1,464	1,973	3,772	5,982	
Depreciation	200	200	200	400	Dixon would invest ~Rs4bn in display modules; Phase 1 would be Rs1.5bn; we assume Rs2bn investment for phase 1 over FY27-29E; incremental investment of Rs2bn in FY30E would lead to additional depreciation
as a % of Sales	*1.6*	*1.2*	*0.6*	*0.8*	
JV PAT (Rs mn)	1,037	1,398	2,719	4,387	
PAT margin (%)	**8.5**	**8.5**	**8.7**	**8.8**	We assume 8% PAT margin on the business, with improvement over time
Dixon share at 74%	768	1,034	2,012	3,246	
26% share minority interest - A	**270**	**363**	**707**	**1,141**	Dixon has 74% stake in the JV with HKC, implying 26% minority stake to be added to the consolidated PAT
PNL under the TLA route with HKC	**FY27E**	**FY28E**	**FY29E**	**FY30E**	**Commentary**
Display Modules Manufacturing	**10.9**	**13.0**	**24.1**	**36.9**	Displays for internal consumption (mobiles and IT hardware) and external consumption
ASP (Rs/unit) - 12% of the BOM Cost	**1,118**	**1,261**	**1,307**	**1,352**	ASP at 12% of Mobile ASP, as display modules are ~12% of BOM
JV revenues (Rs bn)	12,203	16,445	31,437	49,851	
EBITDA (Rs mn)	1,464	1,973	3,772	5,982	
EBITDA margin before Royalty (%)	***12.0***	***12.0***	***12.0***	***12.0***	Per the management, display modules offer healthy double-digit margins; assumed 12%
Royalty - B	**244**	**329**	**629**	**997**	Assumed Royalty at 2% of Revenue
EBITDA after Royalty (Rs mn)	**1,220**	**1,644**	**3,144**	**4,985**	
EBITDA margin after Royalty (%)	***10.0***	***10.0***	***10.0***	***10.0***	
Depreciation	200	200	200	400	Dixon would invest ~Rs4bn in display modules; Phase 1 would be Rs1.5bn; we assume Rs2bn investment for Phase 1 over FY27-29E; incremental investment of Rs2bn in FY30E would lead to additional depreciation
as a % of Sales	*1.6*	*1.2*	*0.6*	*0.8*	
PAT (Rs mn)	**864**	**1,165**	**2,266**	**3,656**	
PAT margin (%)	***7.1***	***7.1***	***7.2***	***7.3***	
Dixon share at 100%	**864**	**1,165**	**2,266**	**3,656**	
Particulars (Rs mn)	**FY27E**	**FY28E**	**FY29E**	**FY30E**	**Commentary**
Saving in Minority Share (A)	270	363	707	1,141	There would be no impact on minority interest under the TLA route - positive PAT impact
Less: Royalty Paid (B)	244	329	629	997	Royalty paid would have an impact on the EBITDA margin of the display business
Benefit to Dixon	**26**	**35**	**78**	**144**	**Net benefit to Dixon under the TLA route**
EPS (Rs)	**229**	**360**	**575**	**905**	
% of EPS	**0.19**	**0.16**	**0.23**	**0.26**	**Impact on EPS under the TLA route vs JV route is less than 1%**

Source: Company, Emkay Research

Display module foray was not hinging on the JV with HKC

With respect to HKC, Dixon's management had explicitly stated the possibility of a royalty-based Technical Licensing Agreement (TLA), which ensures that Dixon's aspirations for backward integration remain on track.

"In any case, the execution of JV or execution of this project is not hinging on the PN3 approval. The project installation, the project implementation is carrying on parallelly"

\- Atul Lall, VC and MD, Dixon Technologies India (Link)

Exhibit 4: We build in 30%/36%/48% revenue/EBITDA/EPS CAGR over FY25-28E in our bull case

Particulars (Rs mn)	FY25	FY26E	FY27E	FY28E	FY25-28E CAGR
Smartphone volumes, incl exports (ex-Samsung, mn units)	**28.3**	**37.5**	**49.3**	**59.5**	**28%**
- Of which Vivo volumes (mn units)			*6.9*	*11.4*	
Smartphone volume growth YoY (%)		*32.7*	*31.4*	*20.6*	
Segmental Revenue					
- Mobiles and EMS	**330,435**	**446,089**	**647,697**	**833,307**	**36%**
-- Mobiles	289,675	366,329	520,622	688,588	33%
-- IT Products	0	14,652	26,195	35,626	
-- Telecom	33,440	58,520	93,632	101,123	45%
-- Other EMS Products	7,320	6,588	7,247	7,971	3%
- Home Appliances	**13,664**	**15,865**	**17,874**	**19,276**	**12%**
- Consumer Electronics	**35,900**	**29,270**	**34,249**	**35,231**	**-1%**
- Lighting	8,602	1,880	0	0	
Consolidated Revenue	**388,601**	**493,104**	**699,820**	**887,815**	**32%**
Growth YoY (%)	*119.7*	*26.9*	*41.9*	*26.9*	
EBITDA	**15,076**	**18,835**	**26,539**	**40,049**	**38%**
EBITDA Margin (%)	*3.9*	*3.8*	*3.8*	*4.5*	
-- of which via component backward integration			*3,234*	*9,679*	
% of Revenue (margin benefit only)			*0.5*	*1.1*	
Minority Interest	1,370	2,156	2,462	3,055	
JV Income	174	220	433	505	
PAT	**6,356**	**8,530**	**13,808**	**21,661**	**50%**
PAT Margin (%)	***1.6***	*1.7*	*2.0*	*2.4*	
			61.9		
EPS (Rs)	**105.5**	**141.6**	**229.2**	**359.5**	**50%**

Source: Company, Emkay Research; Note: FY26E PAT is excluding a one-off gain of Rs5.5bn reported in Q2/Q3; Lighting business moved to JV from Q2

Exhibit 5: Our estimates are unchanged

	FY26E				FY27E				FY28E			
(Rs mn)	**Earlier**	**Revised**	**% Change**	**% YoY**	**Earlier**	**Revised**	**% Change**	**% YoY**	**Earlier**	**Revised**	**% Change**	**% YoY**
Revenue	493,104	493,104	*0.0*	*26.9*	699,820	699,820	*0.0*	*41.9*	887,815	887,815	*0.0*	*26.9*
EBITDA	18,835	18,835	*0.0*	*24.9*	26,539	26,539	*0.0*	*40.9*	40,049	40,049	*0.0*	*50.9*
EBITDAM (%)	*3.8*	*3.8*	*0 bps*	*(6) bps*	*3.8*	*3.8*	*0 bps*	*(3) bps*	*4.5*	*4.5*	*0 bps*	*72 bps*
Adj PAT	8,530	8,530	*0.0*	*34.21*	13,808	13,808	*0.0*	61.9	21,661	21,661	*0.0*	56.9
Adj EPS (Rs)	141.6	141.6	-	34.2	229.2	229.2	-	61.9	359.5	359.5	-	56.9

Source: Company, Emkay Research

Exhibit 6: Dixon clocks in best-in-class EPS CAGR and return ratios

Peer	**CMP (Rs)**	**FY25-28E EPS CAGR**	**EPS (Rs)**				**PER (x)**			**EV/EBITDA (x)**			**RoE (%)**		
			FY25	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**
Dixon Technologies	11,024	50.5%	105.5	141.6	229.2	359.5	77.0	47.6	30.3	34.8	24.7	16.4	23.1	27.5	32.4
Amber Enterprises	5,547	43.1%	71.7	90.4	147.6	209.9	83.1	50.9	35.8	24.8	17.5	13.4	9.9	12.5	15.0
Syrma SGS	724	40.8%	9.6	13.9	20.0	26.9	54.8	38.0	28.3	31.1	22.5	16.9	11.4	13.0	15.2
Kaynes Technology	3,402	41.7%	45.4	68.9	95.2	129.2	55.7	40.3	29.7	37.3	24.6	17.3	12.0	12.9	15.3
PG Electroplast	529	22.4%	10.6	9.8	14.9	19.4	55.4	36.6	28.1	35.6	25.9	20.7	9.0	12.2	13.9

Source: Company, Bloomberg, Emkay Research

Dixon Technologies: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	**176,909**	**388,601**	**493,104**	**699,820**	**887,815**
Revenue growth (%)	45.1	119.7	26.9	41.9	26.9
EBITDA	**6,976**	**15,076**	**18,835**	**26,539**	**40,049**
EBITDA growth (%)	36.1	116.1	24.9	40.9	50.9
Depreciation & Amortization	1,619	2,810	3,879	4,802	6,242
EBIT	**5,357**	**12,266**	**14,956**	**21,737**	**33,807**
EBIT growth (%)	34.6	128.9	21.9	45.3	55.5
Other operating income	-	-	-	-	-
Other income	226	202	1,398	303	455
Financial expense	747	1,544	1,649	1,736	1,895
PBT	**4,836**	**10,924**	**14,706**	**20,304**	**32,367**
Extraordinary items	0	4,600	5,480	0	0
Taxes	1,189	3,372	4,239	4,467	8,157
Minority interest	(72)	(1,370)	(2,156)	(2,462)	(3,055)
Income from JV/Associates	102	174	220	433	505
Reported PAT	**3,677**	**10,956**	**14,010**	**13,808**	**21,661**
PAT growth (%)	43.9	197.9	27.9	(1.4)	56.9
Adjusted PAT	**3,677**	**6,356**	**8,530**	**13,808**	**21,661**
Diluted EPS (Rs)	**61.5**	**105.5**	**141.6**	**229.2**	**359.5**
Diluted EPS growth (%)	43.2	71.5	34.2	61.9	56.9
DPS (Rs)	**3.0**	**5.5**	**8.0**	**12.9**	**20.3**
Dividend payout (%)	**4.9**	**3.0**	**5.7**	**5.7**	**5.7**
EBITDA margin (%)	3.9	3.9	3.8	3.8	4.5
EBIT margin (%)	3.0	3.2	3.0	3.1	3.8
Effective tax rate (%)	24.6	30.9	28.8	22.0	25.2
NOPLAT (pre-IndAS)	**4,040**	**8,480**	**10,645**	**16,954**	**25,288**
Shares outstanding (mn)	60	60	60	60	60

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	120	121	121	121	121
Reserves & Surplus	16,829	29,982	43,509	56,537	76,974
Net worth	**16,949**	**30,102**	**43,630**	**56,658**	**77,094**
Minority interests	276	4,591	6,748	9,210	12,265
Non-current liab. & prov.	259	1,072	1,072	1,072	1,072
Total debt	**4,890**	**6,710**	**7,173**	**8,089**	**8,573**
Total liabilities & equity	**23,028**	**43,251**	**59,607**	**76,426**	**100,777**
Net tangible fixed assets	16,368	23,876	28,997	39,195	49,453
Net intangible assets	307	307	307	307	307
Net ROU assets	-	-	-	-	-
Capital WIP	683	2,570	2,250	3,750	4,125
Goodwill	303	570	570	570	570
Investments [JV/Associates]	200	5,356	5,356	5,356	5,356
Cash & equivalents	**2,087**	**2,635**	**12,859**	**15,346**	**26,668**
Current assets (ex-cash)	46,698	128,819	163,461	231,986	294,306
Current Liab. & Prov.	46,886	124,418	157,877	224,061	284,251
NWC (ex-cash)	**(188)**	**4,401**	**5,585**	**7,926**	**10,055**
Total assets	**23,028**	**43,251**	**59,607**	**76,426**	**100,777**
Net debt	2,803	4,074	(5,686)	(7,256)	(18,095)
Capital employed	23,028	43,251	59,607	76,426	100,777
Invested capital	**19,774**	**32,139**	**38,443**	**50,982**	**63,369**
BVPS (Rs)	283.4	499.6	724.1	940.4	1,279.6
Net Debt/Equity (x)	0.2	0.1	(0.1)	(0.1)	(0.2)
Net Debt/EBITDA (x)	0.4	0.3	(0.3)	(0.3)	(0.5)
Interest coverage (x)	7.5	8.1	9.9	12.7	18.1
RoCE (%)	**28.3**	**39.3**	**33.1**	**33.5**	**39.9**

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	4,836	15,524	20,406	20,737	32,872
Others (non-cash items)	-	-	-	-	-
Taxes paid	(1,218)	(2,760)	(4,239)	(4,467)	(8,157)
Change in NWC	(88)	(1,816)	(1,123)	(2,221)	(2,020)
Operating cash flow	**5,843**	**11,497**	**13,693**	**20,283**	**30,378**
Capital expenditure	(5,686)	(8,956)	(8,681)	(16,500)	(16,875)
Acquisition of business	366	(3,414)	0	0	0
Interest & dividend income	11	81	6,878	303	455
Investing cash flow	**(5,309)**	**(12,289)**	**(1,802)**	**(16,197)**	**(16,420)**
Equity raised/(repaid)	469	1,399	0	0	0
Debt raised/(repaid)	(496)	(117)	463	916	483
Payment of lease liabilities	-	-	-	-	-
Interest paid	(494)	(1,219)	(1,649)	(1,736)	(1,895)
Dividend paid (incl tax)	(179)	(329)	(482)	(780)	(1,224)
Others	-	-	-	-	-
Financing cash flow	**(700)**	**(266)**	**(1,667)**	**(1,600)**	**(2,636)**
Net chg in Cash	(166)	(1,058)	10,223	2,487	11,322
OCF	5,843	11,497	13,693	20,283	30,378
Adj. OCF (w/o NWC chg.)	5,931	13,313	14,816	22,505	32,398
FCFF	157	2,541	5,012	3,783	13,503
FCFE	(579)	1,079	10,242	2,351	12,062
OCF/EBITDA (%)	83.8	76.3	72.7	76.4	75.9
FCFE/PAT (%)	(15.7)	9.8	73.1	17.0	55.7
FCFF/NOPLAT (%)	**3.9**	**30.0**	**47.1**	**22.3**	**53.4**

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	177.4	60.0	77.0	47.6	30.3
EV/CE(x)	29.6	15.8	11.4	8.9	6.7
P/B (x)	38.5	21.8	15.1	11.6	8.5
EV/Sales (x)	3.7	1.7	1.3	0.9	0.7
EV/EBITDA (x)	93.9	43.5	34.8	24.7	16.4
EV/EBIT(x)	122.3	53.4	43.8	30.1	19.4
EV/IC (x)	33.1	20.4	17.0	12.8	10.3
FCFF yield (%)	-	0.4	0.8	0.6	2.1
FCFE yield (%)	(0.1)	0.2	1.5	0.4	1.8
Dividend yield (%)	-	0.1	0.1	0.1	0.2
DuPont-RoE split					
Net profit margin (%)	2.1	1.6	1.7	2.0	2.4
Total asset turnover (x)	8.7	11.7	9.6	10.3	10.0
Assets/Equity (x)	1.4	1.4	1.4	1.4	1.3
RoE (%)	**24.7**	**27.0**	**23.1**	**27.5**	**32.4**
DuPont-RoIC					
NOPLAT margin (%)	2.3	2.2	2.2	2.4	2.8
IC turnover (x)	10.9	15.0	14.0	15.7	15.5
RoIC (%)	**25.0**	**32.7**	**30.2**	**37.9**	**44.2**
Operating metrics					
Core NWC days	(0.4)	4.1	4.1	4.1	4.1
Total NWC days	**(0.4)**	**4.1**	**4.1**	**4.1**	**4.1**
Fixed asset turnover	8.8	13.0	12.4	13.5	13.1
Opex-to-revenue (%)	5.4	3.9	3.4	3.2	3.0

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
30-Jan-26	10,446	15,200	Buy	Chirag Jain
20-Jan-26	10,682	15,200	Buy	Chirag Jain
20-Oct-25	16,075	19,000	Buy	Chirag Jain
23-Jul-25	16,556	19,000	Buy	Chirag Jain
26-Jun-25	14,315	19,800	Buy	Chirag Jain
21-May-25	15,612	19,800	Buy	Chirag Jain
03-Feb-25	14,486	21,100	Buy	Chirag Jain
21-Jan-25	15,144	21,100	Buy	Chirag Jain
14-Jan-25	16,275	20,000	Buy	Chirag Jain

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

[1] An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

[2] Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of March 10, 2026
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of March 10, 2026
5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the March 10, 2026
6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.
CIN - L67120MH1995PLC084899
7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

SESHADRI KUMAR SEN

Digitally signed by SESHADRI KUMAR SEN
Date: 2026.03.10 22:40:23 +05'30'